Company profile
DELCATH SYSTEMS, INC.
NASDAQ:DCTHMedical/Dental Instruments
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Melphalan hydrochloride | approved | — | 0 | — |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06875128 | phase2 | recruiting | 2026-01-29 | 2029-05-01 | Delcath Systems Inc. | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease |
| NCT06607458 | phase2 | recruiting | 2025-08-05 | 2026-12-01 | Delcath Systems Inc. | Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease |
| NCT00324727 | phase3 | completed | 2006-02-01 | 2012-08-01 | Delcath Systems Inc. | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma |
| NCT00096083 | phase2 | completed | 2004-09-01 | 2012-08-01 | Delcath Systems Inc. | Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer |
| NCT02415036 | phase2 | terminated | 2014-06-01 | 2018-10-01 | Delcath Systems Inc. | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 201848 | NDA | DELCATH SYSTEMS INC | ||||
Loading… | ||||||